{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T17:04:02Z","timestamp":1754154242689,"version":"3.41.2"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.esmogo.2024.100082","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:17:40Z","timestamp":1724411860000},"page":"100082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation"],"prefix":"10.1016","volume":"5","author":[{"given":"R.","family":"Veelken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.F.","family":"Struck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Girbardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Seehofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Denecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2679-0672","authenticated-orcid":false,"given":"F.","family":"van B\u00f6mmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.esmogo.2024.100082_bib1","first-page":"1230","article-title":"Ocular melanoma: an overview of the current status","volume":"6","author":"Jovanovic","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"issue":"12","key":"10.1016\/j.esmogo.2024.100082_bib2","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1007\/s12325-016-0424-4","article-title":"Chemosaturation percutaneous hepatic perfusion: a systematic review","volume":"33","author":"Vogel","year":"2017","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100082_bib3","first-page":"384","article-title":"Update on HCC management and review of the new EASL guidelines","volume":"14","author":"Aghemo","year":"2018","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100082_bib4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"suppl 16","key":"10.1016\/j.esmogo.2024.100082_bib5","article-title":"FOCUS phase 3 trial results: percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301\/301A)","volume":"40","author":"Zager","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100082_bib6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00270-015-1276-z","article-title":"Percutaneous isolated hepatic perfusion for the treatment of unresectable liver malignancies","volume":"39","author":"Burgmans","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"10","key":"10.1016\/j.esmogo.2024.100082_bib7","first-page":"937","article-title":"Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers","volume":"186","author":"Vogl","year":"2014","journal-title":"R\u00f6Fo"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100082_bib8","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jso.23501","article-title":"Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience","volume":"109","author":"Forster","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100082_bib9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1245\/s10434-007-9781-1","article-title":"Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations","volume":"15","author":"Miao","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"10.1016\/j.esmogo.2024.100082_bib10","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2005.00.927","article-title":"Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies","volume":"23","author":"Pingpank","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100082_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archsurg.138.3.325","article-title":"Percutaneous isolated hepatic perfusion for chemotherapy: a phase 1 study","volume":"138","author":"Savier","year":"2003","journal-title":"Arch Surg"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100082_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/cells10010070","article-title":"A\u00a0new option for the treatment of intrahepatic cholangiocarcinoma: percutaneous hepatic perfusion with CHEMOSAT Delivery System","volume":"10","author":"Ferrucci","year":"2021","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.esmogo.2024.100082_bib13","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00432-017-2461-z","article-title":"Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors","volume":"143","author":"Kirstein","year":"2017","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.esmogo.2024.100082_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.molimm.2016.02.011","article-title":"Complement factor H modulates the activation of human neutrophil granulocytes and the generation of neutrophil extracellular traps","volume":"72","author":"Schneider","year":"2016","journal-title":"Mol Immunol"},{"key":"10.1016\/j.esmogo.2024.100082_bib15","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s00330-018-5729-z","article-title":"Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival","volume":"29","author":"Marquardt","year":"2019","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100082_bib16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00270-021-02983-2","article-title":"Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers","volume":"45","author":"Veelken","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.esmogo.2024.100082_bib18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/DDDT.S368954","article-title":"Tebentafusp in the treatment of metastatic uveal melanoma: patient selection and special considerations","volume":"17","author":"Montazeri","year":"2023","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100082_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/107327481702400116","article-title":"Chemosaturation with percutaneous hepatic perfusion in unresectable hepatic metastases","volume":"24","author":"Glazer","year":"2017","journal-title":"Cancer Control"},{"issue":"01","key":"10.1016\/j.esmogo.2024.100082_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100082_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.esmogo.2024.100082_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254817","article-title":"Percutaneous hepatic melphalan perfusion: single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery","volume":"16","author":"Struck","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.esmogo.2024.100082_bib23","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2147\/OPTH.S28863","article-title":"Current and emerging treatment options for uveal melanoma","volume":"7","author":"Pereira","year":"2013","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100082_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00534-010-0341-x","article-title":"Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma","volume":"18","author":"Caralt","year":"2011","journal-title":"J\u00a0Hepato Biliary Pancreat Sci"},{"issue":"10","key":"10.1016\/j.esmogo.2024.100082_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.38612","article-title":"Eligibility for human leukocyte antigen-based therapeutics by race and ethnicity","volume":"6","author":"Olivier","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmogo.2024.100082_bib26","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100082_bib27","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/jso.24984","article-title":"Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma","volume":"117","author":"Boone","year":"2018","journal-title":"J\u00a0Surg Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100082_bib28","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","article-title":"Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases","volume":"23","author":"Hughes","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100082_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40644-019-0218-4","article-title":"Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience","volume":"19","author":"Artzner","year":"2019","journal-title":"Cancer Imaging"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100082_bib30","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00270-017-1588-2","article-title":"Percutaneous isolated hepatic perfusion as a treatment for isolated hepatic metastases of uveal melanoma: patient outcome and safety in a multi-centre study","volume":"40","author":"Vogl","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"11","key":"10.1016\/j.esmogo.2024.100082_bib31","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1007\/s00432-020-03289-5","article-title":"Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma","volume":"146","author":"Sch\u00f6nfeld","year":"2020","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"14","key":"10.1016\/j.esmogo.2024.100082_bib32","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.esmogo.2024.100082_bib33","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"15","key":"10.1016\/j.esmogo.2024.100082_bib34","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.3390\/cancers15153776","article-title":"Prognostic factors for postoperative bleeding complications and prolonged intensive care after percutaneous hepatic chemosaturation procedures with melphalan","volume":"15","author":"Struck","year":"2023","journal-title":"Cancers"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T03:19:00Z","timestamp":1753327140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819824000438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":33,"alternative-id":["S2949819824000438"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100082","relation":{},"ISSN":["2949-8198"],"issn-type":[{"type":"print","value":"2949-8198"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100082"}}